Please assess the completion status of the following clinical trial:

Trial Title: Pertubation With Lignocaine in Endometriosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age \> 20 years~* endometriosis verified by laparoscopy~* dysmenorrhea or pelvic pain defined as a pain-score of \>50 mm (VAS)~* normal Fallopian tubes~* regular menstrual cycles 21-35 days~* treatment with oral contraceptives (OC) ongoing \> 1 month and continued during the trial~* previous hormonal treatment discontinued \> 1 month (OC, gestagens) and \> 6 months (GnRH)~* no wish for pregnancy during the study~* normal Pap-smear~* negative Chlamydia-test~* negative pregnancy-test~* informed consent given and signed~Exclusion Criteria:~* Continuous treatment with medication that may increase risk for infection - clinical signs of pelvic inflammatory disease~* hyperreactivity to local anesthesia~* fibroids \> 2 cm~* ongoing treatment with GnRH-analog~* ongoing continuous treatment with high dose gestagens~* pregnancy~* peritubal adhesions~* occluded Fallopian tubes~* inability to understand information or comply with the study procedures~* participation in a clinical study within one year before the present study~* any disease or laboratory finding considered of importance by the investigator not to include the patient

- Gender: FEMALE
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pertubation with Endole® (lignocaine) (Type: EXPERIMENTAL): Three treatments were to be given preovulatory at cycle day 6-12 in three sequential menstrual cycles.
- Placebo (Type: PLACEBO_COMPARATOR): Pertubation with Ringer solution, given preovulatory at cycle day 6-12 in three sequential menstrual cycles.

Based on this trial design, predict the completion outcome and termination type (if applicable).